Urapidil

Urapidil

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C02CA06 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione
CAS Number	34661-75-1 64887-14-5 (HCl)
PubChem CID	5639
ChemSpider	5437
UNII	A78GF17HJS
ChEMBL	ChEMBL279229
CompTox Dashboard (EPA)	DTXSID9021425
ECHA InfoCard	100.047.377
Chemical and physical data
Formula	C20H29N5O3
Molar mass	387.484 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1\C=C(/N(C(=O)N1C)C)NCCCN3CCN(c2ccccc2OC)CC3

Urapidil is a sympatholytic antihypertensive drug. It acts as an α₁-adrenoceptor antagonist and as an 5-HT_1A receptor agonist. Although an initial report suggested that urapidil was also an α₂-adrenoceptor agonist, this was not substantiated in later studies that demonstrated it was devoid of agonist actions in the dog saphenous vein and the guinea-pig ileum. Unlike some other α₁-adrenoceptor antagonists, urapidil does not elicit reflex tachycardia, and this may be related to its weak β₁-adrenoceptor antagonist activity, as well as its effect on cardiac vagal drive. Urapidil is currently not approved by the U.S. Food and Drug Administration, but it is available in Europe.

See also

• Naftopidil